Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focused on niche generic products, has scheduled its Q3 FY2025 financial results release for February 13, 2025. The company will host a conference call on February 14, 2025, at 11:30 AM EST to discuss financial and operating results, along with providing a business update.
Stockholders are invited to submit questions prior to the call, with general questions due by February 12, 2025 (5:00 PM EST) and financial questions by February 13, 2025 (7:00 PM EST). The conference call will be accessible via domestic (1-800-346-7359) and international (1-973-528-0008) dial-in numbers using conference number 98840.
Elite Pharmaceuticals (OTCQB: ELTP), una compagnia farmaceutica specializzata focalizzata su prodotti generici di nicchia, ha programmato il rilascio dei suoi risultati finanziari del Q3 dell'anno fiscale 2025 per il 13 febbraio 2025. L'azienda ospiterà una conferenza telefonica il 14 febbraio 2025, alle 11:30 AM EST per discutere i risultati finanziari e operativi, fornendo anche un aggiornamento aziendale.
Gli azionisti sono invitati a inviare domande prima della chiamata, con le domande generali da presentare entro il 12 febbraio 2025 (5:00 PM EST) e le domande finanziarie entro il 13 febbraio 2025 (7:00 PM EST). La conferenza telefonica sarà accessibile tramite numeri di dial-in nazionali (1-800-346-7359) e internazionali (1-973-528-0008) utilizzando il numero di conferenza 98840.
Elite Pharmaceuticals (OTCQB: ELTP), una empresa farmacéutica especializada en productos genéricos de nicho, ha programado la publicación de sus resultados financieros del Q3 del año fiscal 2025 para el 13 de febrero de 2025. La empresa llevará a cabo una llamada de conferencia el 14 de febrero de 2025, a las 11:30 AM EST para discutir los resultados financieros y operativos, así como para proporcionar una actualización comercial.
Los accionistas están invitados a enviar preguntas antes de la llamada, con las preguntas generales debiendo ser enviadas antes del 12 de febrero de 2025 (5:00 PM EST) y las preguntas financieras antes del 13 de febrero de 2025 (7:00 PM EST). La llamada de conferencia será accesible a través de números de marcación nacionales (1-800-346-7359) e internacionales (1-973-528-0008) utilizando el número de conferencia 98840.
엘리트 제약(OTCQB: ELTP), 틈새 제네릭 제품에 중점을 둔 전문 제약 회사가 2025 회계연도 3분기 재무 결과 발표를 2025년 2월 13일로 예정했습니다. 이 회사는 2025년 2월 14일, EST 기준 오전 11:30에 재무 및 운영 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜을 개최합니다.
주주들은 통화 전에 질문을 제출할 수 있으며, 일반 질문은 2025년 2월 12일(EST 기준 오후 5시)까지, 재무 질문은 2025년 2월 13일(EST 기준 오후 7시)까지 제출해야 합니다. 컨퍼런스 콜은 국번 98840을 사용하는 국내(1-800-346-7359) 및 국제(1-973-528-0008) 전화번호를 통해 접근 가능합니다.
Elite Pharmaceuticals (OTCQB: ELTP), une entreprise pharmaceutique spécialisée axée sur des produits génériques de niche, a prévu la publication de ses résultats financiers du 3ème trimestre de l'exercice 2025 pour le 13 février 2025. L'entreprise organise une conférence téléphonique le 14 février 2025, à 11h30 EST pour discuter des résultats financiers et opérationnels, tout en fournissant une mise à jour sur les activités.
Les actionnaires sont invités à soumettre des questions avant l'appel, les questions générales devant être soumises d'ici le 12 février 2025 (17h00 EST) et les questions financières d'ici le 13 février 2025 (19h00 EST). La conférence téléphonique sera accessible via les numéros de composition nationaux (1-800-346-7359) et internationaux (1-973-528-0008) en utilisant le numéro de conférence 98840.
Elite Pharmaceuticals (OTCQB: ELTP), ein auf Nischen-Generika spezialisiertes Pharmaunternehmen, hat die Veröffentlichung seiner Finanzergebnisse für das 3. Quartal des Geschäftsjahres 2025 für den 13. Februar 2025 angesetzt. Das Unternehmen wird am 14. Februar 2025 um 11:30 Uhr EST eine Telefonkonferenz abhalten, um die finanziellen und betrieblichen Ergebnisse zu besprechen sowie ein Geschäftsupdate zu geben.
Aktionäre sind eingeladen, vor dem Anruf Fragen einzureichen, wobei allgemeine Fragen bis zum 12. Februar 2025 (17:00 Uhr EST) und finanzielle Fragen bis zum 13. Februar 2025 (19:00 Uhr EST) eingereicht werden müssen. Die Telefonkonferenz ist über nationale (1-800-346-7359) und internationale (1-973-528-0008) Rufnummern mit der Konferenznummer 98840 zugänglich.
- None.
- None.
Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025
Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on Thursday, February 13, 2025. Elite's management will host a live conference call on Friday, February 14th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
| Date: | February 14, 2025 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Wednesday, February 12, 2025 Financial questions by 7:00 PM EST on Thursday, February 13, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240333
FAQ
When will Elite Pharmaceuticals (ELTP) release Q3 FY2025 earnings?
How can investors participate in Elite Pharmaceuticals' (ELTP) Q3 2025 earnings call?
What is the deadline for submitting questions for ELTP's Q3 2025 earnings call?
Where can I find the audio replay of ELTP's Q3 2025 earnings call?
